What the research found

This isn't a single study but rather a series of investigations documenting how the peptide market is being reshaped by competing interests — pharmaceutical companies, regulators, content platforms, media outlets, and vendors themselves — each applying different definitions to the same products. The reporting identifies a specific case: retatrutide (developed by Eli Lilly) has been available through grey-market suppliers for years, even as Lilly continues its clinical development programme. Simultaneously, prominent peptide educators on YouTube have disappeared from the platform, coinciding with Lilly's legal actions, though causation remains unclear.

An independent evidence audit examined claims made by three high-profile peptide educators about dementia-related applications. Across 156 checkable claims drawn from their content, the audit compared statements against published literature, guidelines, and clinical trials. The reviewers found substantial variation: one creator was relatively aligned with available evidence, another occupied a middle ground with occasional overstatement, and a third showed notable gaps between the confidence of their peptide-specific claims and what human data actually supports.

The underlying observation is structural rather than sensational: the modern peptide ecosystem blends content creation, audience trust, community-building, vendor relationships, and transactions — often within the same person or organisation. This concentration creates both opportunity and opacity around commercial interests.

Why it matters for you

If you're tracking peptides via MyKine, you're likely drawing on educational content, vendor recommendations, or creator endorsements to inform your protocol choices and biomarker expectations. The evidence audit highlights that not all prominent voices carry equal warrant for their claims. When someone builds an audience primarily through dementia-related peptide content but the human evidence for those applications remains limited, your confidence in their other recommendations — GLP-1 variants, collagen peptides, or emerging compounds — should probably reflect that gap too.

More broadly, this matters for your ability to distinguish between genuine uncertainty and marketing confidence. A creator can disappear from platforms without public explanation of why, which leaves their entire body of prior advice orphaned and unvetted. Conversely, a vendor may be described as "black market" or "illegal" by mainstream media, but operate under regulatory grey zones that differ by jurisdiction. Neither label tells you whether the molecule itself is real, whether it's synthesised competently, or what actual risk profile you're assuming.

For biomarker tracking specifically: if you're measuring HbA1c, lipids, or metabolic parameters to assess GLP-1 or GLP-1R agonist effects, you need to know whether the peptide claims driving your protocol choice rest on solid evidence or influencer confidence. The audit suggests significant variability here.

Caveats

• No causation established: The timing of creator removals and Lilly's legal actions is noted but not proven to be connected.
• Observational and preliminary: This is investigative reporting and an independent evidence audit, not a controlled trial.
• Definitional ambiguity remains unresolved: "Fake," "counterfeit," and "illegal" mean different things depending on jurisdiction, intent, and who is defining them — the reporting documents this confusion rather than resolving it.
• Single-point-in-time audit: The evidence audit reflects current published literature; it doesn't predict how evidence bases will evolve or whether early-stage compounds will eventually show human efficacy.
• No data on actual peptide quality: The reporting addresses claims and definitions, not whether grey-market products are chemically what they claim to be.